openPR Logo
Press release

Major Advancements in Psoriasis Therapeutics in Asia-Pacific Markets to 2024 | Researchmoz

Psoriasis Therapeutics in Asia-Pacific Market

Psoriasis Therapeutics in Asia-Pacific Market

ResearchMoz presents professional and in-depth study of "Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market". This research assessment offers a clear insight about the influential factors that are expected to transform the global market in the near future.

Psoriasis is a common, chronic inflammatory skin condition affecting around 2-3% of the world’s population. While the main cause of psoriasis remains uncertain, immunologic, genetic, and environmental factors appear to play a role. Common symptoms of psoriasis include inflammation, swelling, and patches of red, itchy, flaky skin called skin lesions.

The most common sites of involvement are the scalp, elbows and knees, followed by nails, hands, feet and trunk. It is estimated that up to 30% of people with psoriasis eventually develop psoriatic arthritis. Psoriasis is a serious skin condition that has a significant negative impact on patients’ quality of life, interfering in many aspects of professional and social life.

Men and women are equally likely to get it, and the onset of psoriasis can occur at any age. However, the age of onset frequency proved to be bimodal - the first before 40 years of age and the second between 50 and 60 years of age. The extent and severity of the disease varies greatly between patients and often varies within individuals over the course of time.

Get a Sample PDF at: https://www.researchmoz.us/enquiry.php?type=S&repid=1829068

There are different types of psoriasis, the most common being plaque psoriasis. Around 125 million people worldwide have psoriasis, of which 80% have plaque psoriasis. The current marketed drug landscape in psoriasis includes topical agents, systemic therapies (such as acitretin, cyclosporine and methotrexate) and biologic therapies. In recent years, the discovery of new immunological factors and better understanding of psoriasis have fundamentally changed the treatment of psoriasis and created new biological drugs against specific immunological elements that cause psoriasis.

Both IL-17 and IL-23 are promising targets in the treatment of moderate to severe plaque psoriasis. The biologic drugs targeting these cytokines and their receptors have proven to be effective and safe in clinical trials and have offered greater efficacy than pre-existing biologics, making them an attractive option for use prior to other biologics.

Therefore, during the forecast period, the dominance of TNF-? inhibitors (adalimumab, infliximab and etanercept) and interleukin (IL)-12/23 inhibitor ustekinumab will be challenged by the highly effective IL-17 and IL-23 inhibitor therapies. The late-stage psoriasis pipeline is composed of promising targeted therapies that have potential to achieve approval and launch during the forecast period.

These include Sun Pharma’s tildrakizumab, AbbVie’s risankizumab, Welichem Biotech’s Tapinarof, and UCB’s bimekizumab and certolizumab pegol. These new drugs will supplement current market leaders and offer broader therapeutic options.

Scope

- The Asia-Pacific psoriasis market will be valued at $1,997.3m in 2024, growing from $933.1m in 2017, at a compound annual growth rate (CAGR) of 11.5%.
- What are the key factors driving the Asia-Pacific psoriasis treatment market?
- How will novel IL-23 inhibitor therapy Tremfya, which holds first-to-market advantage, contribute to growth?
- What will be the impact of the new IL-17 and IL-23 inhibitor therapies?
- How will branded therapies be affected by upcoming pipeline therapies?
- The psoriasis pipeline contains a range of molecule types and molecular targets, including those that are well established in psoriasis and novel target therapies.
- Which molecular targets appear most frequently in the pipeline?
- Is there potential for pipeline molecules to address unmet needs within the psoriasis market?
- Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- Which classes of drugs are most prominent in the pipeline?
- How will the approval of risankizumab and tildrakizumab, which hold a key advantage in terms of dosing schedule over IL-23 competitor Tremfya, affect the competitive landscape?
- Various drivers and barriers will influence the market over the forecast period.
- What barriers will limit the uptake of premium-priced therapeutics in the assessed countries?
- What factors are most likely to drive the market in these countries?
- What licensing and co-development deals have occurred within this therapy area since 2007?

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/psoriasis-therapeutics-in-asiapacific-markets-to-2024-increasing-prevalence-advent-of-novel-biologics-and-pipeline-drugs-to-drive-the-market-report.html/toc

Reasons to buy

- Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.
- Visualize the composition of the psoriasis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the psoriasis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict psoriasis market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the psoriasis deals landscape by analyzing trends in licensing and co-development deals.

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ https://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Major Advancements in Psoriasis Therapeutics in Asia-Pacific Markets to 2024 | Researchmoz here

News-ID: 1599179 • Views:

More Releases from Psoriasis Therapeutics in Asia-Pacific Market

Advanced Technologies| Psoriasis Therapeutics in Asia-Pacific Markets will be valued at $1,997.3m in 2024
Advanced Technologies| Psoriasis Therapeutics in Asia-Pacific Markets will be va …
Researchmoz added Most up-to-date research on "Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market" to its huge collection of research reports. Psoriasis is a common, chronic inflammatory skin condition affecting around 2-3% of the world’s population. While the main cause of psoriasis remains uncertain, immunologic, genetic, and environmental factors appear to play a role. Common symptoms of psoriasis

More Releases for ResearchMoz

Global Defoamers Market Research Report 2017-2025 - Researchmoz
Researchmoz added latest report "Defoamers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025". The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. Defoamers Market – Overview Defoamers, or antifoaming agents, are chemical additives that reduce and hamper the formation of foam in industrial processes. Defoamers are generally insoluble in the foaming medium and possess surface active
Global Polyurethane Waterproof Coating Market | ResearchMoz | Research Report
Researchmoz added Most up-to-date research on "Global Polyurethane Waterproof Coating Market | ResearchMoz | Research Report" to its huge collection of research reports. This report researches the worldwide Polyurethane Waterproof Coating market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions. This study categorizes the global Polyurethane Waterproof Coating breakdown data by manufacturers, region, type and application, also analyzes the market
United State | Football Apparel Market For 2017 | ResearchMoz
Researchmoz added Most up-to-date research on "United State | Football Apparel Market For 2017 | ResearchMoz" to its huge collection of research reports. In this report, the United States Football Apparel market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into
Global Cord Blood Banking Industry | Research Report | ResearchMoz
Researchmoz added Most up-to-date research on "Global Cord Blood Banking Industry | Research Report | ResearchMoz" to its huge collection of research reports. The global cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities. Serious threats to the industry include: New accreditation requirements that have increased the cost structure of cord blood banks A decline in cord blood transplants in 2013, within the
New Study Reveals Germany Wealth Report 2016 | Researchmoz
Researchmoz added Most up-to-date research on "Germany Wealth Report 2016" to its huge collection of research reports. This report is the result of WealthInsights extensive research covering the high net worth individual (HNWI) population and wealth management market in Germany. Summary This report reviews the performance and asset allocations of HNWIs and ultra-HNWIs in Germany. It also includes an evaluation of the local wealth management market. Scope Independent market sizing of the German HNWIs for
Global Industry Guide on IT Services 2017 | Researchmoz
Researchmoz added Most up-to-date research on "IT Services Global Industry Guide 2017" to its huge collection of research reports. Global IT Services industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Synopsis Essential resource for top-line data and analysis covering the Global IT